"The company, which focuses on developing treatments for reproductive disorders, said although it reduced its amount of accounts payable and accrued expenses by about $8.9 million since September, the amount of cash on hand is not sufficient to fund future clinical trials of its experimental drugs Androxal and Proellex."
No comments:
Post a Comment